Risankizumab vs Ustekinumab for Crohn's Disease(SEQUENCE Trial)

"Risankizumab is often used as an intervention for patients that may require systemic therapy. It can also treat conditions such as infection, invasive procedure, and dental plaque."

"Eligibility for this trial is restricted to patients that are between 18 and 80 years old."

"This trial is being conducted by Digestive Disease Specialists in Oklahoma City, OK; Mayo Clinic - Rochester in Minnesotan Oklahoma City, OK; Mayo Clinic - Rochester in Minnesota; Covenant Health in Edmonton, AB; and 55 other locations."

"The primary objective of this study, which will be evaluated over the course of 24 weeks, is to assess the percentage of patients who achieve endoscopic remission. Secondary objectives include measuring the percentage of participants who are able to achieve steroid-free remission (defined as discontinuation of corticosteroid use for 90 days while also achieving clinical remission at 48 weeks for those taking steroids at baseline), the percentage of participants who are able to achieve both endoscopic and steroid-free remission (defined as meeting criteria for both endoscopic remission and not receiving steroids at Week 48), and the percentage of participants who experience an endoscopic response at Week 24 (defined"

"This specific clinical trial is no longer looking for new patients, however there are 258 other trials related to ileocolitis and 61 studies involving Risankizumab that are currently enrolling participants."

"This clinical trial is testing a potential new medication for ileocolitis. The study requires that patients are between 18-80 years old and around 527 people will be accepted in total."

"Safety is always our top priority. Risankizumab has undergone Phase 3 trials, which means that there is data to support its efficacy and safety. We've given it a score of 3."

"The clinical trial in question, which was created on September 30th 2020 and edited most recently on August 24th 2022, is not presently looking for participants. That being said, there are 319 other medical trials that are currently recruiting patients."

"Risankizumab was first investigated in 2011 by the researchers at Memorial Sloan Kettering Cancer Center. Since then, 175 clinical trials have been completed while 61 are ongoing. The majority of these live trials are being conducted out of Oklahomag Cancer Center. Since then, 175 clinical trials have been completed while 61 are ongoing. The majority of these live trials are being conducted out of Oklahoma City, Oklahoma."